ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Network Pharmacology-Based Analysis on the Effects and Mechanism of the Wang-Bi Capsule for Rheumatoid Arthritis and Osteoarthritis

Wu, Shan-Shan; Hao, Li-Jun; Shi, Yuan-Yuan; Lu, Zhuo-Jian; Yu, Jia-Lin; Jiang, Si-Qi; Liu, Qing-Ling; Wang, Ting*; Guo, Shi-Ying*; Li, Ping*; Li, Fei*云南大学
ACS OMEGA2022-3-8DOI: 10.1021/acsomega.1c06729
6被引15阅读
引用收藏
分享

摘要

Wang-Bi capsule (WB) is a traditional Chinese medicine (TCM)-based herbal formula, and it has been used in the treatment of rheumatoid arthritis (RA) in China for many years. Additionally, WB is also used as a supplement to the treatment of osteoarthritis (OA) in clinical practice. Our research aimed to reveal the therapeutic effects and underling mechanism of WB on RA and OA through computational system pharmacology analysis and experimental study. Based on network pharmacology analysis, a total of 173 bioactive compounds interacted with 417 common gene targets related to WB, RA, and OA, which mainly involved the PI3K-Akt signaling pathway. In addition, the serine-threonine protein kinase 1 (AKT1) might be a core gene protein for the action of WB, which was further emphasized by molecular docking. Moreover, the anti-inflammatory activity of WB in vitro was confirmed by reducing NO production in lipopolysaccharide (LPS)-induced RAW264.7 cells. The anti-RA and OA effects of WB in vivo were confirmed by ameliorating the disease symptoms of collagen II-induced RA (CIA) and monosodium iodoacetate-induced OA (MIA) in rats, respectively. Furthermore, the role of the PI3K-Akt pathway in the action of WB was preliminarily verified by western blot analysis. In conclusion, our study elucidated that WB is a potentially effective strategy for the treatment of RA and OA, which might be achieved by regulating the PI3K-Akt pathway. It provides us with systematic insights into the effects and mechanism of WB on RA and OA.

学科与关键词

关键词
ATTENUATES OSTEOARTHRITISCHONDROCYTESAPOPTOSIS
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
ACS OMEGA
发表日期
2022-03-08
卷期
第 7 卷, 第 9 期
页码
7825-7836
DOI
10.1021/acsomega.1c06729
成果收录
SCIE
资助标注
National Key R&D Program of China [2019YFC1711000]; National Natural Science Foundation of China [81873185, 81860773]; Natural Science Foundation of Jiangsu province [BK20181327]; Xinjiang Science Fund for Distinguished Young Scholar Project [2018Q003]

作者

  • W

    Wu, Shan-Shan (第一作者)

    china pharmaceut univ

  • H

    Hao, Li-Jun

    china pharmaceut univ

查看全部 11 位作者收起作者
  • S

    Shi, Yuan-Yuan

    xinjiang med univ · china pharmaceut univ

  • L

    Lu, Zhuo-Jian

    xinjiang med univ · china pharmaceut univ

  • Y

    Yu, Jia-Lin

    china pharmaceut univ

  • J

    Jiang, Si-Qi

    china pharmaceut univ

  • L

    Liu, Qing-Ling

    china pharmaceut univ

  • W

    Wang, Ting (通讯)

    yunnan univ

  • G

    Guo, Shi-Ying (通讯)

  • L

    Li, Ping (通讯)

    china pharmaceut univ

  • L

    Li, Fei (通讯)

    xinjiang med univ · china pharmaceut univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417